Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M532Revenue $M9.8Net Margin (%)-18,394.6Altman Z-Score-4.1
Enterprise Value $M455EPS $-4.8Operating Margin %-18,458.0Piotroski F-Score1
P/E(ttm)--Beneish M-Score226Pre-tax Margin (%)-18,394.6Higher ROA y-yN
Price/Book4.010-y EBITDA Growth Rate %-4.9Quick Ratio3.2Cash flow > EarningsY
Price/Sales18,0135-y EBITDA Growth Rate %28.7Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-78.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-97.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.3ROIC % (ttm)-451.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
$ 11.75-30%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
$ 11.75-48%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 11.75-63%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 11.75-54%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 11.75-60%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 11.75-69%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 11.75-59%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 11.75-56%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
$ 11.7580%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
$ 11.75137%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
$ 11.7549%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
$ 11.7521%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82-0.59view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82-0.59view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95-15.77view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56-6.45view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-68.28view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-66.4view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-64.05view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-62.22view
Price Ben GilDirector 2013-08-19Buy500$31.18-62.32view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-69.48view

Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
    Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
    Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 

    More From Other Websites
    Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma Feb 10 2016
    Sarepta Hits 52-Week Low; Eteplirsen Review Period Extended Feb 09 2016
    Sarepta Therapeutics Dropped 10% Following FDA News Feb 08 2016
    Sarepta's Duchenne drug decision delayed: Why it could help win approval Feb 08 2016
    [$$] FDA Extends Sarepta's Muscular Dystrophy Drug Deadline Feb 08 2016
    Sarepta says FDA delays decision on muscle-wasting disorder drug Feb 08 2016
    8:31 am Sarepta Therapeutics announces that the FDA will require additional time to complete its... Feb 08 2016
    Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen Feb 08 2016
    Will Sarepta reverse after steep drop? Feb 05 2016
    It’s Time to Buy This Biotech Gem Feb 04 2016
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 02 2016
    Top 10 BioFlash stories in January: Duchenne news dominates once again Feb 01 2016
    3 Key FDA Decisions Expected in February Jan 31 2016
    Structural Volatility Won't End For Several Years, Derivatives Strategist Says Jan 27 2016
    Bragar Eagel & Squire, P.C. Is Investigating the Officers and Directors of Sarepta Therapeutics,... Jan 26 2016
    Duchenne drug by Cambridge's Catabasis looks safe in early trial Jan 25 2016
    IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Sarepta... Jan 24 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)